Circassia Pharmaceuticals has announced the US launch of Duaklir aclidinium bromide/formoterol fumarate DPI for the treatment of COPD. The FDA approved Duaklir Pressair in April 2019. Circassia acquired the US rights to Duaklir and Tudorza Pressair from AstraZeneca in 2017.
Circassia Chief Executive Steve Harris commented, “The US launch of Duaklir represents a major strategic milestone for Circassia, significantly boosting our portfolio of marketed respiratory products and strengthening our offering of COPD treatments alongside our aclidinium monotherapy, Tudorza. With the LAMA / LABA market predicted to grow strongly in the United States in the coming years, Duaklir has the opportunity to make an important contribution to the treatment of this serious disease. We look forward to our dedicated COPD commercial team successfully introducing this new therapeutic option, as we make Duaklir available across the United States.”
Read the Circassia Pharmaceuticals press release.
